Nanoparticles of Gd2O3 pegylated and conjugated to amylovis with potential application in the detection of alzheimer by MRI
Keywords:
alzheimer disease; contrast agent; nanoparticles; gadolinium oxide; MRI.Abstract
Specific contrast agents facilitate the use of Magnetic Resonance Imaging (MRI) in the early diagnosis of Alzheimer's disease (AD). In the present work, a procedure for the synthesis of a potential MRI contrast agent based on PEGylated Gd2O3 particles is developed for conjugation to Amylovis®, a family of compounds that has shown a high affinity for the pathological structures present in AD. The products obtained were characterized by FT-IR, ICP, TGA, DLS and SEM. Amylovis-functionalized Gd2O3 particles showed a spherical morphology, with an average hydrodynamic diameter of 2.5 μm. These particles presented an adequate value of the ratio between the longitudinal (r1) and transversal (r2) relaxivities (r2/r1 = 2.4). This suggests that once these particles have a hydrodynamic diameter smaller than 200 nm, they could be used as a potential contrast agent for MRI.
References
SÁNCHEZ-MÁRQUEZ, N. I., BILBAO-FUENTES, D. B. “Dinámica familiar de pacientes con enfermedad de Alzheimer antes y después del inicio de la enfermedad”. Pensando Psicología. 2018, 14(24). ISSN 2382-3984
AZRIA, D.; BLANQUER, S.; VERDIER, J.M.; BELAMIE, E. “Nanoparticles as contrast agents for brain nuclear magnetic resonance imaging in Alzheimer's disease diagnosis”. Journal of Materials Chemistry B. 2017, 5(35), 7216-7237. ISSN 2050-7518
HAJIPOUR, M. J. et al. “Advances in alzheimer’s diagnosis and therapy: The implications of nanotechnology”. Trends in biotechnology. 2017, 35 (10), 937953. ISSN: 0167-7799
RASTOGI, N.; TYAGI, N.; SINGH, O.; KUMAR, B. S. H.; ROY, R. “Mn(II) based T1 and T2 potential MRI contrast agent appended with tryptamine: Recognition moiety for Aβ-plaques”. Journal of Inorganic Biochemistry. 2017, 177, 76-81. ISSN: 0162-0134
MATHARU, B.; SPENCER, N.; HOWE, F.; AUSTEN, B. “Gadolinium complexed Aβ-binding contrast agents for MRI diagnosis of Alzheimer's Disease”. Neuropeptides. 2015, 53, 63-70. ISSN: 0143-4179
COURANT, T.; ROULLIN, G. V.; CADIOU, C.; CALLEWAERT, M. et al. “Biocompatible nanoparticles and gadolinium complexes for MRI applications”. Comptes Rendus Chimie. 2013, 16 (6), 531-539. ISSN: 1631-0748
CARRASCO, S.; CALLES, C.; FERNÁNDEZ, C.; LAFUENTE, J. “Contrastes basados en gadolinio utilizados en resonancia magnética”. Radiología. 2014, 56, 21-28. ISSN: 0033-8338
WANG, C. et al. “Amyloid‐β Oligomer‐Targeted Gadolinium‐Based NIR/MR Dual‐Modal Theranostic Nanoprobe for Alzheimer's Disease”. Advanced Functional Materials. 2020, 30 (16), 1909529. ISSN: 1616-3028
TELGMANN, L.; SPERLING, M.; KARST, U. “Determination of gadolinium based MRI contrast agents in biological and environmental samples: A review”. Analytica Chimica Acta. 2013, 764, 1-16. ISSN: 0003-2670
SABLÓN-CARRAZANA, M. et al. “Drug Development in Conformational Diseases: A Novel Family of Chemical Chaperones that Bind and Stabilise Several Polymorphic Amyloid Structures”. PLOS ONE. 2015, 10 (9):e0135292 ISSN: 1932-6203
SALERNO, M.; PORQUERAS, D. S. D. “Alzheimer's disease: The use of contrast agents for magnetic resonance imaging to detect amyloid beta peptide inside the brain”. Coordination Chemistry Reviews. 2016, (15), 27-34. ISSN: 0010-8545
ZHANG, C. et al. “Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice”. Biomaterials. 2014, 35 (1), 456-465. ISSN: 0142-9612
MANCINI, S. et al. “The hunt for brain Aβ oligomers by peripherally circulating multi-functional nanoparticles: Potential therapeutic approach for Alzheimer disease”. Nanomedicine: Nanotechnology, Biology and Medicine. 2016, 12 (1), 43-52. ISSN: 1549-9642
FERNÁNDEZ-GÓMEZ, I. et al. “Diabetes Drug Discovery: hIAPP1–37 Polymorphic Amyloid Structures as Novel Therapeutic Targets”. Molecules. 2018, 23, 686. ISSN: 1420-3049.
RIVERA-MARRERO, S. et al. “[18F] Amylovis as a Potential PET Probe for β-Amyloid Plaque: Synthesis, In Silico, In vitro and In vivo Evaluations”. Curr Radiopharm. 2019, 12(1), 58-71. ISSN: 1874-4710
MARRERO-RIVERA, S. et al. “A new naphthalene derivative with anti-amyloidogenic activity as potential therapeutic agent for Alzheimer's disease”. Bioorganic & Medicinal Chemistry. 2020, 28 (20), 115-700. ISSN 0968-0896
GAYATHRI, T.; SUNDARAM, N. M.; KUMAR, R. A. “Gadolinium Oxide Nanoparticles for Magnetic Resonance Imaging and Cancer Theranostics”. Journal of Bionanoscience. 2015, 9 (6), 409-423. ISSN: 1557-7910
AHRÉN, M. et al. “A simple polyol-free synthesis route to Gd2O3 nanoparticles for MRI applications: an experimental and theoretical study”. Journal of Nanoparticle Research. 2012, 14 (8), 1006. ISSN: 1388-0764
NAKAMOTO, K., “Infrared and Raman Spectra of Inorganic and Coordination Compounds”. Part B: Applications in Coordination, Organometallic, and Bioinorganic Chemistry. John Wiley & Sons, Inc. ed.; Wiley. 2009. ISSN: 978-0-471-74493-1
AGHAZADEH, M. “Preparation of Gd2O3 Ultrafine Nanoparticles by Pulse Electrodeposition Followed by Heat-treatment Method”. Journal of Ultrafine Grained and Nanostructured Materials. 2016, 49 (2), 80-86. ISSN: 2423-6845
AHMAD, M. et al. “Bovine serum albumin (BSA) and cleaved-BSA conjugated ultrasmall Gd2O3 nanoparticles: Synthesis, characterization, and application to MRI contrast agents”. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2014, 450, 67-75. ISSN: 0927-7757
RIYAHI-ALAM, S.; HAGHGOO, S.; GORJI, E.; RIYAHI-ALAM, N. “Size reproducibility of gadolinium oxide based nanomagnetic particles for cellular magnetic resonance imaging: effects of functionalization, chemisorption and reaction conditions”. Iranian journal of pharmaceutical research: IJPR. 2015, 14 (1), 3. ISSN: 1735-0328
Downloads
Published
How to Cite
Issue
Section
License
This journal provides immediate open access to its content, based on the principle that offering the public free access to research helps a greater global exchange of knowledge. Each author is responsible for the content of each of their articles.
